PRF: Consolidated Unaudited Interim Report for 3rd quarter

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
PRF: Consolidated Unaudited Interim Report for 3rd quarter and 9 months of 2013

Tallinn, Estonia, 2013-11-12 08:00 CET (GLOBE NEWSWIRE) --  

The financial results of Premia Foods during the 3rd quarter and 9 months, 2013, may be characterized by the increase of turnover for the third quarter in a row, considerably improved profitability and decreased operating costs.

For the first time in the company’s history, Premia reached organic quarterly increase of turnover by over 10% as the increase of turnover of the 3rd quarter was 13.8%. The EBIT in the 3rd quarter of 2013 increased 2.6 times, if compared to the same period of the previous year, reaching 2.7 million euro; in the summary of 9 months the corresponding figure was 3.1 million euro and the growth was 4.6 times. The net profit increased during the 3rd quarter of 2013, if compared to the same period of the previous year, by 1.9 times, reaching 2.1 million euro; in the summary of 9 months the net profit increased, if compared to the same period of the previous year, by 2.8 times, reaching 1.9 million euro.  

The main financial results of the operations of the company during the reporting period are the following:

  • The unaudited consolidated turnover of the 3rd quarter of 2013 of Premia Foods increased by 13.8%, i.e. 3.3 million euro, if compared to the results of the 3rd quarter of 2012, reaching 26.9 million euro. The unaudited consolidated turnover of 9 months of 2013 was 72.9 million euro, having increased on a yearly basis by 9.2%, i.e. 6.1 million euro. In the summary of 9 months of 2013, the turnover increased in all the business segments and target markets of Premia Foods. 
  • The company’s gross profit of the 3rd quarter of 2013 was 7.1 million euro, remaining at the same level as during the same period of the previous year. In the summary of 9 months of 2013, Premia earned a gross profit of 18.8 million euro, which is 0.4 million euro less than the result of the same period of the previous year, whereas the main reason thereof is the decreased gross margin of the fish business segment. During the 3rd quarter of 2013, the ice cream business segment and the frozen goods business segment earned 0.5 million euro more gross profit, if compared to the results of the previous year;  in the summary of 9 months the referred business segments earned 1.6 million more gross profit, if compared to the 9 months of 2012.
  • Premia’s EBITDA of the 3rd quarter of 2013 was 3.3 million euro, exceeding the result of the previous year by 1.8 times. In the summary of 9 months of 2013, the EBITDA was 5.0 million euro, exceeding the result of the previous year by 1.6 times. The EBITDA increased in the summary of 9 months of 2013 in all the business segments, the largest contribution came from the ice cream business segment.
  • The positive impact of livestock revaluation on the operating profit of the company during the 3rd quarter was 1.3 million euro, if compared to the previous year; in the summary of 9 months of 2013, the positive impact on the operating profit was 2.4 million euro. 
  • The EBIT in the 3rd quarter of 2013 was 2.7 million euro, exceeding the result of the previous year by 2.6 times. In the summary of 9 months, the EBIT was 3.1 million euro, which exceeds the result of the previous year by 4.6 times. Also the operating profit improved during the 9 months of 2013 in all the business segments, the largest increase here came once again from the ice cream business segment.
  • The net profit of the 3rd quarter of 2013 was 2.1 million euro, exceeding the result of the previous year by 1.9 times. In the summary of 9 months of 2013, Premia earned a net profit of 1.9 million euro, exceeding the result of the previous year by 2.8 times.
  • The operating expense ratio decreased during the 3rd quarter by 4.6 percentage points, if compared to the same period of 2012, and in the summary of 9 months by 2.8 percentage points. In total, the operating expenses, on an annual basis, decreased during the 3rd quarter of 2013 by 0.4 million euro, in the summary of 9 months by 0.5 million euro. 
                    KEY RATIOS  
                     
Profit & Loss, EUR mln   Q1 Q2 Q3 9m 2013   Q1 Q2 Q3 9m 2012
Sales   18,3 27,8 26,9 72,9   17,1 26,1 23,6 66,8
Gross profit   3,8 8,0 7,1 18,8   4,2 7,9 7,1 19,3
EBITDA from operations   -0,4 2,4 2,1 4,1   0,0 2,7 2,1 4,9
EBITDA   -0,7 2,4 3,3 5,0   -0,6 1,9 1,9 3,2
EBIT   -1,3 1,7 2,7 3,1   -1,4 1,1 1,0 0,7
Net profit   -1,2 1,0 2,1 1,9   -1,2 0,8 1,1 0,7
Gross margin    20,6% 28,6% 26,4% 25,8%   24,5% 30,4% 30,2% 28,8%
Operational EBITDA margin   -2,2% 8,8% 7,8% 5,7%   0,1% 10,5% 8,9% 7,3%
EBIT margin   -7,3% 6,2% 10,0% 4,2%   -8,3% 4,0% 4,4% 1,0%
Net margin    -6,5% 3,7% 7,7% 2,6%   -6,9% 2,9% 4,7% 1,0%
Operating expense ratio   27,1% 22,7% 21,6% 23,4%   29,7% 24,0% 26,1% 26,2%
   Balance Sheet, EUR mln     31.12.12   31.03.13   30.06.13   30.09.13     31.12.11   31.03.12   30.06.12   30.09.12
Net debt   13,8 13,2 15,2 14,6   11,3 12,2 12,0 10,9
Equity   36,5 35,3 36,1 38,2   40,5 39,3 39,8 37,1
Working capital   12,1 10,4 10,8 13,1   12,8 12,0 12,4 9,7
Assets   63,2 62,4 67,7 66,1   64,1 64,2 68,5 65,4
Liquidity ratio   1,91 1,73 1,58 1,86   2,19 1,91 1,70 1,55
Equity ratio    58% 57% 53% 58%   63% 61% 58% 57%
Gearing ratio   28% 27% 30% 28%   22% 24% 23% 23%
Net debt-to-EBITDA   2,71 2,80 3,46 3,31   2,55 1,98 2,19 2,06
ROE   0% 0% 1% 3%   -1% 1% 0% -1%
ROA   0% 0% 1% 2%   -1% 0% 0% -1%

Consolidated statement of financial position

EUR ‘000 30/09/2013 31/12/2012 30/09/2012  
Cash and cash equivalents 1,254 1,357 1,490  
Receivables and prepayments 9,091 8,152 8,422  
Inventories 10,032 10,308 10,520  
Biological assets 7,953 5,631 6,789  
Total current assets 28,330 25,448 27,221  
         
Deferred income tax assets 393 473 477  
Long-term financial investments 127 131 88  
Investment property 2,084 2,084 2,084  
Property, plant and equipment 12,712 12,499 13,000  
Intangible assets 22,424 22,548 22,571  
Total non-current assets 37,741 37,735 38,220  
TOTAL ASSETS 66,070 63,183 65,441  
         
Borrowings 5,373 3,953 4,088  
Payables and prepayments 9,895 9,399 13,480  
Total current liabilities 15,268 13,352 17,568  
         
Borrowings 10,433 11,239 8,350  
Deferred income tax liabilities 858 659 901  
Government grants 1,322 1,479 1,537  
Total non-current liabilities 12,613 13,377 10,788  
Total liabilities 27,881 26,729 28,356  
         
Share capital 19,342 19,342 19,342  
Share premium 16,026 16,026 16,026  
Statutory capital reserve 6 6 6  
Other reserves 57 42 36  
Currency translation differences 665 485 508  
Retained earnings 2,093 553 1,167  
Equity attributable to equity holders of the parent 38,189 36,453 37,085  
Total equity 38,189 36,453 37,085  
TOTAL LIABILITIES AND EQUITY 66,070 63,183 65,441  

Consolidated statement of comprehensive income

EUR ‘000 Q3 2013 Q3 2012 9m 2013 9m 2012  
Revenue 26,854 23,591 72,906 66,788  
Cost of goods sold -19,759 -16,461 -54,089 -47,537  
Gross profit 7,094 7,130 18,817 19,251  
           
Operating expenses -5,788 -6,159 -17,046 -17,497  
Sales and marketing expenses -4,868 -5,183 -14,165 -14,048  
General and administrative expenses -920 -976 -2,881 -3,449  
Other income and expenses, net 93 131 199 250  
Revaluation of biological assets 1,287 -54 1,118 -1,326  
Operating profit 2,685 1,048 3,088 678  
           
Finance income -17 128 20 150  
Finance costs -250 -112 -836 -456  
           
Profit before income tax 2,418 1,065 2,272 372  
           
Corporate income tax -343 42 -345 315  
           
Net profit for the period 2,075 1,107 1,927 687  
           
Other comprehensive income          
Currency translation differences 57 45 180 117  
Other comprehensive income 57 45 180 117  
Total comprehensive income 2,132 1,152 2,107 804  
           
Net profit for the period:          
  Attributable to equity holders of the parent 2,075 1,107 1,927 687  
Net profit for the period 2,075 1,107 1,927 687  
           
Comprehensive income for the period:          
  Attributable to equity holders of the parent 2,132 1,152 2,107 804  
Total comprehensive income 2,132 1,152 2,107 804  
           
Earnings per share          
Basic earnings per share (EUR) 0.05 0.03 0.05 0.02  
Diluted earnings per share (EUR) 0.05 0.03 0.05 0.02  

         Additional information:                    Katre Kõvask          AS Premia Foods          Chairman of the Management Board          T: +372 6 033 800          katre.kovask@premia.ee          www.premiafoods.eu

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Voter Events by Valley Community Healthcare Aim to Empower

Updated Category News Views 17

Here's a game-changer for the community. Valley Community Healthcare (VCH) is stepping up, proving that healthcare doesn't just stick to check-ups and prescriptions. It's about the whole shebang—community empowerment included. This October, VCH is hosting two incredible voter events, collaborating with the Los Angeles County Registrar-Recorder's Mobile Voting Program....

Continue Reading
LG OLED evo W6: UAE Roadshow Starts with a Bang

Updated Category News Views 28

They've done it again, folks. LG Electronics is out there kicking up a storm with their all-new OLED evo W6 True Wireless Wallpaper TV, and they're bringing the action straight to the UAE's doorsteps. Imagine taking a stroll and stumbling upon this technological marvel at some fancy spot like The Lotus Lounge at Anantara The Palm Dubai Resort. This ain't just a TV, it's a...

Continue Reading
Innventure Faces Major Lawsuit Over Misleading Investors

Updated Category News Views 30

Missteps at Innventure: A Costly Lesson in Investor Trust The stock market is no stranger to drama, but Innventure's saga feels like a page ripped right out of a thriller novel. You’ve got accusations, alleged fabrications, and a swift drop in stock prices that’s left some investors shaking their heads. The company, nestled under the ticker NASDAQ:INV, finds itself...

Continue Reading
Hyliion Class Action Deadline Nears for Investors

Updated Category News Views 29

Potential Shockwaves for Hyliion Investors Investors are having a showdown with Hyliion (NYSE:HYLN) these days. With the looming October 27, 2026, deadline to jump into a securities class action, it seems Hyliion's latest escapade smells worse than a fish market on a hot day. We’ve got allegations here stronger than your uncle’s morning coffee. Understanding the Legal...

Continue Reading
Weifang's Cultural Resurgence: A Global Epigraphy Fest

Updated Category News Views 18

A Historical Meltdown into Global Recognition Welcome to the ride where ancient stones talk and cultural borders vanish. We're diving into the beating heart of Weifang, a place you're probably hearing about now because the town's hosting a packed international media tour. And, for a change, this isn't just another tourist trap; it's a cultural adrenaline shot to the arm,...

Continue Reading
AEVEX Facing Class Action Deadline Amid Stock Turmoil

Updated Category News Views 26

Investors are no strangers to the rough and tumble of stock markets, but things get downright messy when trust is shattered. That's the sorry saga unfolding with AEVEX, where shareholders are feeling the heat after a sharp nosedive in stock value. The clock is ticking to join the class action, and any AEVEX investor worth their salt should pay attention. Unraveling...

Continue Reading
Masimo's smartSET™ Revolutionizes Patient Monitoring

Updated Category News Views 25

Breaking Ground in Patient Monitoring Let's dive into the gritty details behind Masimo's latest FDA-nod: the smartSET™ system. This gizmo ain't your ordinary pulse oximeter; it's a next-gen hand-holder for the medical world, poised to ride the AI wave straight into the clinic. They've cracked open a new way for clinicians to peek behind the curtain of patient vitals,...

Continue Reading

Top 5 Most Recently Viewed Articles

Legal Action Initiated for Investors of Telix Pharmaceuticals Ltd.

Updated Category News Views 95

Class Action Lawsuit for Telix Pharmaceuticals Ltd. Investors Levi & Korsinsky, LLP has initiated a notification for investors in Telix Pharmaceuticals Ltd. The class action lawsuit aims to provide compensation for investors who have suffered losses. This action pertains to allegations of securities fraud impacting the company's reputation and financial integrity....

Continue Reading
Parcel Perform Elevates E-commerce Delivery with AI Decision Intelligence

Updated Category News Views 199

Revolutionizing E-commerce Delivery with AI In today’s landscape, AI is significantly altering the way consumers engage with e-commerce. Parcel Perform is at the forefront of this shift, urging businesses to 'Think Bigger on AI.' With Artificial Intelligence redefining the customer journey, a superior delivery experience has become paramount for success in online...

Continue Reading
Exploring New Innovations and Trends in China's Development

Updated Category News Views 321

Emerging Terms and Innovation from China's Latest Sessions In recent discussions, many revolutionary buzzwords have captured attention, signaling China’s aspirations for progress. New phrases like "funds and resources used to serve the people," "embodied AI," and "gazelle companies" reflect the ongoing transformation in sectors spanning government finance, technology,...

Continue Reading
Digital Realty Welcomes Paula Cogan as New EMEA Director

Updated Category News Views 265

Digital Realty Appoints Paula Cogan as Managing Director Digital Realty (NYSE: DLR), a leading global provider specializing in cloud- and carrier-neutral data center solutions, has announced the appointment of Paula Cogan as Managing Director and Head of the EMEA region. This strategic move is set to amplify Digital Realty’s growth in this essential market segment....

Continue Reading
Investors Urged to Act Before Deadline in DXC Class Action

Updated Category News Views 41

DXC Technology got hit with a class action lawsuit back in 2024 that sent ripples through the investor community. The Law Offices of Frank R. Cruz put out the call, reminding shareholders about an impending deadline to file a lead plaintiff motion. You buying DXC during the specified dates? You might wanna pay attention—this ain't just another legal shuffle. Financial...

Continue Reading